Manage cookies
Title A multicomponent smoking cessation program for adults with Type 2 Diabetes Mellitus (DiMe-SALUD2 project): A study protocol of a randomized controlled trial
Authors LÓPEZ NUÑEZ, CARLA, FERNÁNDEZ ARTAMENDI, SERGIO, RUIZ ARANDA, DESIREE, RESURRECCIÓN MENA, DAVINIA MARÍA, NAVAS CAMPAÑA, DESIRÉE MARÍA
External publication No
Means Contemp. Clin. Trials Commun.
Scope Article
Nature Científica
SJR Quartile 2
Web https://www.scopus.com/inward/record.uri?eid=2-s2.0-85202971813&doi=10.1016%2fj.conctc.2024.101361&partnerID=40&md5=c02680a43f164481072ef8e5d7b818f4
Publication date 01/01/2024
ISI 001308947600001
Scopus Id 2-s2.0-85202971813
DOI 10.1016/j.conctc.2024.101361
Abstract Background: Tobacco use represents a significant public health burden, being especially harmful for smokers with Type 2 Diabetes Mellitus (T2DM). Effective smoking cessation interventions are required for this vulnerable population. The goal is to describe a study protocol of a randomized controlled trial (RCT) aimed at analyzing the effectiveness and efficiency of a multicomponent smoking cessation intervention for T2DM smokers, including a training protocol on healthy lifestyle habits and self-management of T2DM (DiMe-SALUD2 project). Methods: This RCT will assign participants to: (1) Control Group (n = 30), including a brief psychoeducation advice about smoking cessation; (2) Cognitive-behavioral treatment (CBT) for smoking cessation (n = 30), based on a multicomponent program implemented in group-based sessions over an eight-week period; and (3) CBT plus DiMeSALUD2 protocol (n = 30), which will develop an additional psychoeducational protocol specifically designed to improve healthy lifestyle habits. Participants will be assessed at baseline, post-treatment and several follow-ups (1-, 6- and 12-months). Primary outcomes will include smoking abstinence (24-h point prevalence abstinence at post-treatment and 7-day point prevalence at follow-ups) and smoking continuous abstinence. Secondary outcomes will include treatment retention, changes in smoking patterns and nicotine dependence, as well as the impact on T2DM clinical variables, mental health, and quality of life. Discussion: The DiMeSALUD2 program could assist T2DM smokers in quitting tobacco use and improving their overall quality of life. This project will help incorporating improvements in routine clinical practice with T2DM patients, offering a smoking cessation program adapted to their specific needs. Trial registration: ClinicalTrials.gov. Identifier: NCT05885659. Date of registration: June 2nd, 2023. © 2024
Keywords adult; Article; clinical article; clinical effectiveness; clinical outcome; clinical trial protocol; cognitive behavioral therapy; controlled study; diabetic patient; follow up; healthy lifestyle; human; mental health; non insulin dependent diabetes mellitus; point prevalence; psychoeducation; quality of life; randomized controlled trial; self care; self monitoring; smoking; smoking cessation; smoking cessation program; tobacco dependence; tobacco use; vulnerable population
Universidad Loyola members